TrialArthritis research & therapy2015

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.

William Stohl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.